The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines

Vaccine

Volumn 19, Issue 23-24, 2001, Pages 3058-3066

  Von Hunolstein, Christina ^a   Mariotti, Sabrina ^a   Teloni, Raffaela ^a   Alfarone, Giovanna ^a   Romagnoli, Giulia ^a   Orefici, Graziella ^a   Nisini, Roberto ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Anti toxin antibodies; CpG motifs; Glycoconjugate vaccines

Indexed keywords

ACT HIB; DIPHTHERIA ANTIBODY; DIPHTHERIA TOXOID; DIPLOID CELL VACCINE; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; OLIGODEOXYNUCLEOTIDE; POLYSACCHARIDE VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIPHTHERIA; DNA SEQUENCE; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HOST; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TETANUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BASE SEQUENCE; CPG ISLANDS; DIPHTHERIA TOXOID; FEMALE; GLYCOCONJUGATES; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID;

EID: 0035972043     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00048-2     Document Type: Article

References (50)

1. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM 197
2. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugated
3. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine
4. Will adjuvants be needed for vaccines of the future
5. Declining incidence of Haemophilus influenzae type b since introduction of vaccination
6. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines
7. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy
8. Interaction of Haemophilus influenzae type b coniugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests
9. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukine 6, interleukine 12, and interferon γ
10. Immune activation by bacterial DNA: A new genetic code
11. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
12. DNA from bacteria, but not from vertebrates induces interferons, activates Natural Killer cells and inhibits tumor growth
13. CpG motifs as immune adjuvants
14. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
15. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
16. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
17. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
18. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
19. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
20. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
21. Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations
22. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
23. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
24. CpG DNA as mucosal adjuvant
25. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine
26. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
27. DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen
28. Quantitative and qualitative analysis of anti tetanus toxoid antibody response in the elderly. Humoral immune response enhancement by thymostimulin
29. Assay of tetanus vaccine
30. Micro cell culture method for determination of diphtheria toxin and antitoxin titers using Vero cells. I. Studies on factors affecting the toxin and antitoxin titration
31. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA
32. Immunological concepts of vaccine adjuvant activity
33. Introduction: The role of innate immunity in the adaptive immune response
34. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
35. Intermolecular cooperativity: A clue to why mice have IgG3
36. Lymphokine control of in vivo immunoglobulin isotype selection
37. Monoclonal antibodies as probes of tetanus toxin structure and function
38. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model
39. Evaluation of toxin neutralisation in test systems for diphtheria antibody assessment
40. Neutralization of diphtheria toxin by human immunoglobulin classes and subunits
41. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197
42. Serum antibodies against Haemophilus influenzae type b and tetanus at 2.5 years of age: A follow-up of 2 different regimens of infant vaccination
43. Studies on a Hib-tetanus toxoid conjugate vaccine: Effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine
44. Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies
45. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides
46. Adjuvants - A balance between toxicity and adjuvanticity
47. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract
48. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs
49. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
50. Immune responses to nucleic acid vaccines to rabies virus